Results 41 to 50 of about 49,464 (141)

Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature

World Journal of Surgical Oncology, 2021
Background Capecitabine is a prodrug that is enzymatically converted to its active form, fluorouracil (also called 5-fluorouracil), which is commonly used as adjuvant chemotherapy in colorectal cancer patients. Severe gastrointestinal bleeding induced by
You Zou, Shuang Liu, Jianhong Wu, Zhen Sun   +3 more
doaj   +1 more source

Adherence to Capecitabine Among Patients With Gastrointestinal Cancer: A Prospective Cohort Study

Acta Medica Iranica, 2023
Adherence to capecitabine, an effective oral chemotherapy agent, is essential in achieving treatment response in cancer. In this study, we aimed to investigate factors associated with non-adherence to capecitabine in a sample of patients with ...
Ahmad Khajeh-Mehrizi, Seyed Amir Hossein Emami, Seyed Reza Safaee Nodehi, Zahra Jahangard-Rafsanjani, Kamran Roudini, Mohammad Reza Dabiri, Seyed Amir Mahdi Emami   +6 more
doaj   +1 more source

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

npj Breast Cancer, 2017
Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast
Jo Anne Zujewski, Lawrence Rubinstein
doaj   +1 more source

Drug-Induced Hand-Foot Syndrome in Cancer Patients Receiving Capecitabine in A Tertiary Care Hospital

Pakistan Armed Forces Medical Journal, 2023
Objective: To determine the frequency of hand-foot syndrome and associated factors among patients receiving Capecitabine for the management of cancer in a tertiary care setting. Study Design: Cross-sectional study.
Ibtisam Idrees, Riaz Ahmad, Muhammad Umair, Anum Zargham, Mir Jalal-ud- Din, Tahir Manoor Lone   +5 more
doaj   +1 more source

Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2013
BackgroundCapecitabine has proven effective as a chemotherapy for metastatic breast cancer. Though several Phase II/III studies of capecitabine as neoadjuvant chemotherapy have been conducted, the results still remain inconsistent.
Qiuyun Li, Yi Jiang, Wei Wei, Huawei Yang, Jianlun Liu   +4 more
doaj   +1 more source

Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Aims: This study used an animal xenograft model of gastric cancer induction to investigate the therapeutic effects of capecitabine polyamidoamine (PAMAM) dendrimer complex against cancer and its potential side effects.
Sharareh Jafari, Fatemeh Nabavizadeh, Jalal Vahedian, Mehdi Ardestani, Hedayat Samandari, Ali Mehrjerdi   +5 more
doaj   +1 more source

Evaluation of Nanocarrier Targeted Drug Delivery of Capecitabine-PAMAM Dendrimer Complex in a Mice Colorectal Cancer Model

Acta Medica Iranica, 2016
Capecitabine, an effective anticancer drug in colorectal cancer chemotherapy, may create adverse side effects on healthy tissues. In the present study, we first induced colon adenocarcinoma with azoxymethane, a carcinogen agent, and then investigated the
Fatemeh Nabavizadeh, Hafseh Fanaei, Alireza Imani, Jalal Vahedian, Fahimeh Asadi Amoli, Jamal Ghorbi, Hamid Sohanaki, Seyed Mehdi Mohammadi, Ravieh Golchoobian   +8 more
doaj  

Management of severe capecitabine-induced corneal toxicity

American Journal of Ophthalmology Case Reports
Purpose: To describe the clinical presentation and management of severe capecitabine-induced corneal toxicity. Observations: A 71-year-old woman presented with severe bilateral vision loss. Four months earlier, capecitabine was initiated for a metastatic
Mathieu Heyvaert, Hannelore Denys, Jo Van Dorpe, Dimitri Roels   +3 more
doaj   +1 more source

Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study

Breast
Purpose: To determine the beneficiaries of capecitabine in patients with triple-negative breast cancer (TNBC) who failed to achieve pathological complete response (pCR) by analyzing the efficacy of the drug in different HER2 statuses and TNM stages ...
Youzhao Ma, Mingda Zhu, Jingyang Zhang, Dechuang Jiao, Yangyang Hou, Xiuchun Chen, Zhenzhen Liu   +6 more
doaj   +1 more source

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

BMC Cancer, 2022
Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the
Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori   +11 more
doaj   +1 more source